Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00606749
Other study ID # KC706-C08
Secondary ID
Status Completed
Phase Phase 2
First received January 22, 2008
Last updated June 18, 2008
Start date November 2007
Est. completion date June 2008

Study information

Verified date June 2008
Source Kemia, Inc
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether KC706 is effective in the prevention and healing of blisters in patients with pemphigus vulgaris, while the patient remains on stable doses of corticosteroids and/or immunosuppressants.


Description:

The present study is designed to follow-up on pre-clinical observations that administration of KC706 is associated with prevention of the development of lesions in a mouse model of PV. Patients participating in this study will be those with active disease in spite of ongoing treatment with corticosteroids and/or immunosuppressive agents. The dose chosen for this clinical study is 300 mg once daily. The primary assessment of interest will be pemphigus lesion status during dosing with KC706.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date June 2008
Est. primary completion date June 2008
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- At least 18 years of age;

- Diagnosis of pemphigus vulgaris

- Patients must be taking and require either corticosteroid therapy or immunosuppressive therapy or both;

- Immunosuppressive therapy, if any,should have been administered at a stable dose for at least 60 days prior to the Baseline Visit and be well-tolerated, without the expectation that there will be a need to increase that dose during the next 30 days;

- Corticosteroids, if any, should have been administered at a stable dose for at least 30 days prior to the Baseline Visit without expectation that there will be a need to increase that dose during the next 30 days;

- Patients should have active PV skin, scalp or mucosal lesions that meet at least one of the following criteria at the Baseline Visit:

- > 3 new lesions/week every week in the previous 3 weeks (skin, scalp, and/or mucosal), with healing occurring at a rate to match the appearance of new lesions; or

- At least 3 active, established lesions with a Pemphigus Lesion Score of at least 2; skin or scalp lesions must be = 5mm in diameter to qualify; there is no size requirement for mucosal lesions; or,

- 1 large active established skin, scalp, or mucosal lesion > 10 mm;

- Accessibility to veins suitable for venipuncture;

- Patients must be cooperative, able to read, understand and give informed consent, and able to adhere to the study visit schedule and protocol requirements; and,

- Patients must be willing to follow adequate contraceptive measures during the study (both sexes).

Exclusion Criteria:

- Any history of opportunistic infections within 3 months prior to receiving study drug;

- Infection with HIV;

- Past or present diagnosis of hepatitis confirmed by serology or elevated hepatic enzymes;

- History of alcoholic liver disease or cirrhosis;

- Clinically significant concurrent medical disease or laboratory abnormalities evidenced by one or more of the following:

- Hepatobiliary AST or ALT = 1.5 × upper limit of normal (ULN);alkaline phosphatase = 1.5 × ULN; or, total bilirubin > 90% of the ULN;

- Renal serum creatinine > 1.5 mg/dL; or, significant proteinuria > 2+ on urinary dip test;

- Hematologic hemoglobin < 11 mg/dL; leukocytes < 3.5 × 109/L; neutrophils < 1.5 × 109/L; or, platelets < 100 × 109/L;

- Presence or history of malignancy;

- Uncontrolled diabetes (defined as diabetes requiring hospitalization or emergency care in the 3 months prior to first dose of study drug);

- History or suspicion of Gilbert's syndrome;

- Significant blood loss (> 500 mL) within 28 days prior to receipt of study drug;

- Use of an investigational drug within 30 days of screening, or longer if that drug is expected to have long-acting effects (e.g., modulation of B-cell activity);

- Use of Rituximab within the past 6 months;

- Use of intravenous IgG within the past 3 months,

- Current or recent history (within 12 months of screening) of drug or substance abuse, including alcohol;

- Known or suspected pregnancy; nursing mothers;

- Clinically significant abnormality on the screening physical examination performed at the Baseline Visit, laboratory testing, vital signs or electrocardiogram suggestive of significant unstable medical condition other than the disease under study;

- Condition which, in the opinion of the Investigator, could interfere with participation in the study or would put the patient at unacceptable risk;

- History of noncompliance with medical regimens.

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
KC706
300 mg once daily (QD) for 12 weeks.

Locations

Country Name City State
United States Victoria Werth, MD Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Kemia, Inc

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To evaluate the ability of KC706 to prevent the appearance of new lesions and heal existing lesions, while maintaining stable doses of corticosteroids and/or immunosuppressants in patients with pemphigus vulgaris. 16 weeks No
Secondary Evaluate the safety of KC706 in patients with PV and to assess plasma levels of KC706 with once daily dosing. 16 weeks Yes
See also
  Status Clinical Trial Phase
Recruiting NCT04422912 - A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV) Phase 1
Recruiting NCT05635266 - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Recruiting NCT04117529 - Phenotypic and Functional Characterisation of Human B-cell Response in Pemphigus N/A
Completed NCT03334058 - A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With Pemphigus Phase 2
Terminated NCT03239470 - Polyclonal Regulatory T Cells (PolyTregs) for Pemphigus Phase 1
Terminated NCT00429533 - Efficacy of Dapsone as a Steroid Sparing Agent in Pemphigus Vulgaris Phase 2
Recruiting NCT05594472 - Ozonated Olive Oil in Treatment of Pemphigus Vulgaris and Bullous Pemphigoid Phase 3
Completed NCT02383589 - A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV) Phase 3
Withdrawn NCT03780166 - A Study of the Safety and Tolerability of INCB050465 in Pemphigus Vulgaris Phase 2
Recruiting NCT04096222 - Comparative Analysis of the Th17 Cellular Response in Active and Inactive Pemphigus Vulgaris Patients
Not yet recruiting NCT03177213 - Serum IL-21 Levels in Patients With Pemphigus Vulgaris N/A
Completed NCT00135720 - Study of Etanercept (Enbrel) in the Treatment of Pemphigus Vulgaris Phase 2
Completed NCT00063752 - Safety Study of PI-0824 to Treat Pemphigus Vulgaris Phase 1
Terminated NCT03075904 - A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus) Phase 1/Phase 2
Terminated NCT04598477 - A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus) Phase 3
Completed NCT02704429 - A Study of PRN1008 in Adult Patients With Pemphigus Vulgaris Phase 2
Completed NCT00626678 - Azathioprine Versus Placebo in Pemphigus Vulgaris Treated With Prednisolone Phase 2
Active, not recruiting NCT05338112 - Role of Tzanck Smear in Determining Pemphigus Vulgaris Disease Activity
Completed NCT06167408 - Identifying Factors Influencing In-Hospital Relapse in Pemphigus Patients
Recruiting NCT05303272 - A Study to Evaluate Efficacy and Safety of Abatacept in Participants of Pemphigus Vulgaris (PV) Phase 4